nintedanib

Known as: Intedanib, Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate, methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate 
An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities… (More)

Topic mentions per year

Topic mentions per year

1984-2018
05010019842018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Idiopathic pulmonary fibrosis (IPF) is a disease with relentless course and limited therapeutic options. Nintedanib (BIBF-1120… (More)
Is this relevant?
2016
2016
BACKGROUND Nintedanib is a tyrosine kinase inhibitor that has recently been shown to slow disease progression in idiopathic… (More)
Is this relevant?
2016
2016
RATIONALE In the two replicate, placebo-controlled, 52-week, phase III INPULSIS trials, nintedanib 150 mg twice daily… (More)
Is this relevant?
Review
2015
Review
2015
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive diffuse parenchymal lung disease of unknown origin, with a… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
2015
2015
Nintedanib (Ofev(®)) is an orally available, small, multiple receptor tyrosine kinase inhibitor developed by Boehringer Ingelheim… (More)
Is this relevant?
2015
2015
A randomised, double-blind, phase II, dose escalation trial was conducted to assess the safety, tolerability and pharmacokinetics… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis. The kinase inhibitor nintedanib… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clinical development for the treatment of idiopathic pulmonary… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
AIMS The aim of this article was to evaluate afatinib (BIBW 2992), an ErbB family blocker, and nintedanib (BIBF 1120), a triple… (More)
Is this relevant?
2012
2012
Nintedanib (BIBF 1120) is a small, orally available, triple angiokinase inhibitor in phase III development (various indications… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?